Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nesp’s Biosame Switches Rapid but Expected: Kyowa Kirin President
February 7, 2020
- Keytruda Stays Atop Encise’s January Drug Ranking
February 7, 2020
- Zeria Licenses Acofide to Spanish Pharma in 13 Latin American Countries
February 7, 2020
- Kyowa Kirin Nets 12.6% Growth on Positive Sales Overseas; Biosame Trounces Nesp in Q4
February 6, 2020
- Janssen, Mitsubishi Tanabe Expand Copromotion Deal for Stelara
February 6, 2020
- Takeda’s April-Dec. Underlying Sales Sag 1.2% as Hemophilia Meds Falter; Outlook Lifted after Buyout Cost Adjustment
February 5, 2020
- Mitsubishi Tanabe’s April-December Sales Fall 10.5% as Gilenya Feud Continues
February 5, 2020
- Collategene Generates Only 4 Million Yen in 4 Months
February 5, 2020
- Zeria, Kyowa Kirin to End Asacol Collaboration at March-End
February 5, 2020
- Kyowa Hakko Bio Staffers Hid GMP Violations, Fearing Supply Halt: Report
February 4, 2020
- Shionogi Cuts Full-Year Guidance as Xofluza Sales Freefall
February 4, 2020
- Oncolys Hopes for Chugai’s Participation in US Development of Telomelysin: Chief
February 4, 2020
- Bayer, Nippon Kayaku to Copromote Prostate Cancer Med Nubeqa
February 4, 2020
- EU Filing Pulled for Opdivo/Yervoy Combo in Frontline NSCLC
February 4, 2020
- MSD to Transfer Japan Distribution Rights for DPP-4 Inhibitor Marizev to Kissei
February 4, 2020
- Towa Completes Buyout of Pensa Investments
February 4, 2020
- Daiichi Sankyo Espha to Launch Zetia AG in June
February 4, 2020
- Astellas’ 9-Month Sales Dip 1.6%, but in Positive Territory If Forex Impact Excluded
February 3, 2020
- Daiichi Sankyo Enjoys 7.7% Rise in April-December Sales; Enhertu Off to Solid Start
February 3, 2020
- Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
February 3, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…